Literature DB >> 8765836

Anti-pneumococcal antibody response in normal subjects: a meta-analysis.

E S Go1, Z K Ballas.   

Abstract

BACKGROUND: The diagnosis of anti-polysaccharide antibody deficiency is based on the presence of normal serum immunoglobulin levels and the lack of specific antibody response to polysaccharide antigens, such as the pneumococcal vaccine. However, a normal response to pneumococcal vaccine is not well defined. "Modified meta-analysis" was undertaken in an attempt to define the normal antibody response to pneumococcal vaccine.
METHODS: Studies identified by a MEDLINE search were selected. Data of the normal control groups, rather than the patient groups, were collated for analysis.
RESULTS: Twenty-three studies fulfilled the selection criteria. Prevaccination antibody titers, postvaccination titers, and post- to prevaccination titer ratios varied widely. On the basis of weighted mean ratios, serotype 8 appeared to be the most antigenic. It appeared that normal subjects do not mount a response of even a twofold increase in antibody titer to all the serotypes present in the vaccine. Moreover, no minimal absolute antibody level that could be of diagnostic value, either before or after vaccination, was evident.
CONCLUSION: Response to pneumococcal vaccine among normal subjects varies widely. Better designed and prospective studies are needed to define the parameters of a normal antibody response to pneumococcal vaccine so that uniform guidelines of interpretation can be formulated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765836     DOI: 10.1016/s0091-6749(96)70244-0

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  27 in total

1.  Phenotypic analysis of pneumococcal polysaccharide-specific B cells.

Authors:  Noor Khaskhely; Jason Mosakowski; Rebecca S Thompson; Sadik Khuder; S Louise Smithson; M A Julie Westerink
Journal:  J Immunol       Date:  2012-01-23       Impact factor: 5.422

2.  Characterization of specific antibody deficiency in adults with medically refractory chronic rhinosinusitis.

Authors:  Tara F Carr; Alan P Koterba; Rakesh Chandra; Leslie C Grammer; David B Conley; Kathleen E Harris; Robert Kern; Robert P Schleimer; Anju T Peters
Journal:  Am J Rhinol Allergy       Date:  2011 Jul-Aug       Impact factor: 2.467

3.  Dexamethasone treatment has no effect on the formation of pneumococcal antibodies during community-acquired pneumonia.

Authors:  Suzan P van Mens; Sabine C A Meijvis; Jan C Grutters; Bart J M Vlaminckx; Willem J W Bos; Ger T Rijkers
Journal:  Clin Vaccine Immunol       Date:  2012-02-29

4.  Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination.

Authors:  J B Rubins; M Alter; J Loch; E N Janoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

5.  Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia.

Authors:  O Sanal; F Ersoy; L Yel; I Tezcan; A Metin; H Ozyürek; S Gariboglu; S Fikrig; A I Berkel; G T Rijkers; B J Zegers
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

6.  Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study.

Authors:  A Chioato; E Noseda; S D Felix; M Stevens; G Del Giudice; S Fitoussi; A Kleinschmidt
Journal:  Clin Vaccine Immunol       Date:  2010-10-20

7.  Longitudinal analysis of pneumococcal antibodies during community-acquired pneumonia reveals a much higher involvement of Streptococcus pneumoniae than estimated by conventional methods alone.

Authors:  Suzan P van Mens; Sabine C A Meijvis; Henrik Endeman; Heleen van Velzen-Blad; Douwe H Biesma; Jan C Grutters; Bart J M Vlaminckx; Ger T Rijkers
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

8.  Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors.

Authors:  B L Ferry; S A Misbah; P Stephens; Z Sherrell; H Lythgoe; E Bateman; C Banner; J Jones; N Groome; H M Chapel
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

9.  Antibody response to pneumococcal vaccination as a function of preimmunization titer.

Authors:  Nathaniel D Hare; Brian J Smith; Zuhair K Ballas
Journal:  J Allergy Clin Immunol       Date:  2008-10-25       Impact factor: 10.793

10.  Kinetics of IgM and IgA antibody response to 23-valent pneumococcal polysaccharide vaccination in healthy subjects.

Authors:  Katharina Schütz; Richard G Hughes; Antony Parker; Isabella Quinti; Vojtech Thon; Monica Cavaliere; Martina Würfel; Wilhelm Herzog; J Engelbert Gessner; Ulrich Baumann
Journal:  J Clin Immunol       Date:  2012-09-25       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.